JP2022535986A5 - - Google Patents
Info
- Publication number
- JP2022535986A5 JP2022535986A5 JP2021573749A JP2021573749A JP2022535986A5 JP 2022535986 A5 JP2022535986 A5 JP 2022535986A5 JP 2021573749 A JP2021573749 A JP 2021573749A JP 2021573749 A JP2021573749 A JP 2021573749A JP 2022535986 A5 JP2022535986 A5 JP 2022535986A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- general formula
- alkyl
- halo
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1908453.2A GB201908453D0 (en) | 2019-06-12 | 2019-06-12 | Compounds for treating respiratory disease |
| GB1908453.2 | 2019-06-12 | ||
| PCT/GB2020/051414 WO2020249956A1 (en) | 2019-06-12 | 2020-06-12 | Modulators of tmem16a for treating respiratory disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535986A JP2022535986A (ja) | 2022-08-10 |
| JP2022535986A5 true JP2022535986A5 (cg-RX-API-DMAC7.html) | 2023-06-13 |
| JP7862174B2 JP7862174B2 (ja) | 2026-05-19 |
Family
ID=67386340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573749A Active JP7862174B2 (ja) | 2019-06-12 | 2020-06-12 | 呼吸器の疾患を処置するためのtmem16aのモジュレータ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12415793B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3983069A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7862174B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114269433B (cg-RX-API-DMAC7.html) |
| GB (1) | GB201908453D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020249956A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201908453D0 (en) | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
| BR112022021391A2 (pt) * | 2020-06-30 | 2023-01-10 | Bayer Ag | N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4 |
| US11331322B1 (en) | 2021-09-15 | 2022-05-17 | Santen Pharmaceutical Co., Ltd. | Medicament for preventing and/or treating dry eye |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4746653A (en) * | 1986-02-28 | 1988-05-24 | Ciba-Geigy Corporation | Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals |
| GB9515975D0 (en) * | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
| EP1032265B1 (en) * | 1997-11-20 | 2003-10-29 | Cerus Corporation | New psoralens for pathogen inactivation |
| JP2004518723A (ja) * | 2001-02-14 | 2004-06-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ピリミジンマトリックスメタロプロテイナーゼ阻害剤 |
| DOP2002000332A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| DE10138578A1 (de) * | 2001-08-06 | 2003-02-27 | Bayer Ag | Heterocyclylarylsulfonamide |
| US6924276B2 (en) * | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| US6933298B2 (en) * | 2001-12-08 | 2005-08-23 | Aventis Pharma Deutschland Gmbh | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases |
| DE10160357A1 (de) * | 2001-12-08 | 2003-06-18 | Aventis Pharma Gmbh | Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen |
| DE10251019A1 (de) * | 2002-11-02 | 2004-05-19 | Aventis Pharma Deutschland Gmbh | Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen |
| DE10300017A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Selektive MMP 13 Inhibitoren |
| US20050004111A1 (en) * | 2003-01-03 | 2005-01-06 | Aventis Pharma Deutschland Gmbh | Selective MMP-13 inhibitors |
| US20060173183A1 (en) * | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| AU2006332694A1 (en) * | 2005-12-30 | 2007-07-12 | Alantos Pharmaceuticals, Holding, Inc. | Substituted bis-amide metalloprotease inhibitors |
| GB0614570D0 (en) * | 2006-07-21 | 2006-08-30 | Glaxo Group Ltd | Compounds |
| US20110269834A1 (en) * | 2008-08-21 | 2011-11-03 | The Board Of Trustees Of The University Of Illinois | Compounds and methods for treating respiratory diseases |
| FR2958849A1 (fr) * | 2010-04-14 | 2011-10-21 | Boiron | Medicament homeopathique a activite anti-cancereuse |
| CN107441097A (zh) * | 2010-04-16 | 2017-12-08 | 阿西纳斯公司 | 用于预防和治疗癌症的组合物以及方法 |
| EP2630122B1 (en) * | 2010-10-18 | 2016-11-30 | RaQualia Pharma Inc | Arylamide derivatives as ttx-s blockers |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| AR091022A1 (es) * | 2012-05-11 | 2014-12-30 | Abbvie Inc | Inhibidores del nampt |
| US9505743B2 (en) * | 2012-10-15 | 2016-11-29 | Aquilus Pharmaceuticals, Inc. | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases |
| ES2885823T3 (es) * | 2013-06-03 | 2021-12-15 | Univ Bar Ilan | Liposomas para modulación de proteína de síndrome de Wiskott-Aldrich |
| EP3020710A4 (en) * | 2013-07-11 | 2016-12-14 | Consejo Superior De Investig Científicas (Csic) | OXAZOLIDINONE DERIVATIVES AS PPAR LIGANDS |
| CN104672241B (zh) * | 2015-01-29 | 2018-04-24 | 王磊 | 吡咯并[2,3-d]嘧啶类化合物及其用途 |
| SG11201803242TA (en) * | 2015-10-29 | 2018-05-30 | Effector Therapeutics Inc | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 |
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| JP7116745B2 (ja) * | 2017-04-28 | 2022-08-10 | レセプトス・リミテッド・ライアビリティ・カンパニー | 新規なglp-1受容体モジュレーター |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| WO2019079609A1 (en) * | 2017-10-20 | 2019-04-25 | The Regents Of The University Of California | SEH / PDE4 DOUBLE INHIBITORS AVAILABLE ORAL |
| CN107954977A (zh) * | 2017-12-15 | 2018-04-24 | 上海鼎雅药物化学科技有限公司 | 雷替曲塞中间体的合成方法 |
| GB201801355D0 (en) * | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| GB201908453D0 (en) | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
-
2019
- 2019-06-12 GB GBGB1908453.2A patent/GB201908453D0/en not_active Ceased
-
2020
- 2020-06-12 WO PCT/GB2020/051414 patent/WO2020249956A1/en not_active Ceased
- 2020-06-12 CN CN202080043484.1A patent/CN114269433B/zh active Active
- 2020-06-12 EP EP20734265.0A patent/EP3983069A1/en active Pending
- 2020-06-12 JP JP2021573749A patent/JP7862174B2/ja active Active
-
2021
- 2021-12-10 US US17/547,967 patent/US12415793B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2763936C1 (ru) | Производные 1,3,4-оксадиазола, как ингибитор гистондезацетилазы 6 и содержащая их фармацевтическая композиция | |
| JP5578083B2 (ja) | 2h−クロメン化合物及びその誘導体 | |
| JPS63258416A (ja) | カルバゾリル−(4)−オキシ−プロパノ−ルアミン誘導体を含有し血管拡張作用及び/又はβ−受容体閉塞作用を有する薬剤 | |
| RU2203897C2 (ru) | Производные бензамидина, способ их получения, фармацевтическая композиция, способ ее получения и лекарственное средство | |
| KR101666729B1 (ko) | Mgat2 억제제로서의 아릴 디히드로피리디논 및 피페리디논 | |
| US20040019113A1 (en) | Phosphate transport inhibitors | |
| EP1308438B1 (en) | 3-substituted urea derivatives and medicinal use thereof | |
| HUE026249T2 (en) | Acrylamide derivatives may be used as inhibitors of mitochondrial permeability transition | |
| JP2021512143A5 (cg-RX-API-DMAC7.html) | ||
| JP2007509852A5 (cg-RX-API-DMAC7.html) | ||
| WO2001025190A1 (en) | Novel diarylamide derivatives and use thereof as medicines | |
| JP2001509166A (ja) | 糖尿病および肥満の治療のためのβ▲下3▼作動薬としてのチアゾールベンゼンスルホンアミド | |
| KR20120092655A (ko) | Cns 장애 치료용 옥사졸린 유도체 | |
| KR20070057965A (ko) | 염증 및 면역 관련 용도를 위한 화합물 | |
| JP2756975B2 (ja) | ピリジニウム誘導体 | |
| KR20060066711A (ko) | 칼슘이온-방출-활성화-칼슘이온 채널을 조절하는 방법 | |
| JP2008502614A5 (cg-RX-API-DMAC7.html) | ||
| JP2006528617A (ja) | 5−ht2b受容体アンタゴニスト | |
| JPWO2005026127A1 (ja) | プラスミノゲンアクチベータインヒビター−1阻害剤 | |
| JP2008516902A5 (cg-RX-API-DMAC7.html) | ||
| CN101420950B (zh) | 杜兴肌营养不良的治疗 | |
| JP2002503247A (ja) | Pge2アゴニストおよびアンタゴニストとして有用なオキサゾール化合物 | |
| CN102030700A (zh) | 苯甲酰胺基羧酸类化合物及其制法和药物用途 | |
| MX2011007048A (es) | Toluidin sulfonamidas y su uso. | |
| JP5161873B2 (ja) | (2r)−2−[(4−スルホニル)アミノフェニル]プロパンアミド類と、それらを含有する医薬組成物 |